Edgewise Therapeutics, Inc. EWTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $151.39M+19.2% | $126.97M+39.7% | $90.91M+68.2% | $54.03M+67.9% | ||
| $40.02M+25.6% | $31.87M+35.9% | $23.45M+33.1% | $17.63M+59.9% | ||
| $191.41M+20.5% | $158.83M+38.9% | $114.36M+59.6% | $71.66M+65.8% | ||
| -$191.41M-20.5% | -$158.83M-38.9% | -$114.36M-59.6% | -$71.66M-65.8% | ||
| -$167.8M-25.4% | -$133.81M-33.6% | -$100.16M-48.1% | -$67.64M-58.0% | ||
| -$1.64-13.1% | -$1.45+8.2% | -$1.58-25.4% | -$1.26+75.2% | ||
| -$189.37M-20.8% | -$156.78M-38.9% | -$112.88M-58.3% | -$71.29M-66.1% | ||
| -$191.41M-20.5% | -$158.83M-38.9% | -$114.36M-59.6% | -$71.66M-65.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Edgewise Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.